Lack of effect of rapamycin in anti-CCP antibody production in a rheumatoid arthritis kidney allograft recipient

Clinical and Experimental Rheumatology

Volumn 23, Issue 4, 2005, Pages 529-531

  Lopez Hoyos, Marcos ^a   Rodrigo, E ^a   Fernandez Fresnedo, G ^a   Martinez Taboada, V M ^a   Valero, R ^a   Arias, M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Anti cyclic citrullinated peptides antibodies; Cyclosporine; Kidney transplantation; Rapamycin; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; PREDNISOLONE; RAPAMYCIN; RHEUMATOID FACTOR;

AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SIROLIMUS;

EID: 26844470146     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. SCHELLEKENS G, VISSER H, De JONG B et al.: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63.
2. Van VENROOIJ WJ, HAZES JM, VISSER H: Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002; 60: 383-8.
3. GOLDBACH-MANSKY R, LEE J, McCOY A et al.: Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236-43.
4. VISSER H, Le CESSIE S, VOS K, BREEDVELD FC, HAZES JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
5. MEYER O, LABARRE C, DOUGADOS M et al.: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-6.
6. LOPEZ-HOYOS M, MARQUINA R, TAMAYO E et al.: Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibodies in mice. Arthritis Rheum 2003; 48: 2353-61.
7. MOTA A, ARIAS M, TASKINEN EI et al.: Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-61.
8. CARLSON RP, HARTMAN DA, TOMCHEK LA et al.: Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 1993; 266: 1125-38.
9. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24
10. LOPEZ-HOYOS M, RUIZ de ALEGRIA C, BLANCO R et al.: Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology 2004; 43: 655-7.
11. CONSTANTINESCU AR, LIANG M, LASKOW DA: Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation. Am J Kidney Dis 2002; 40: 407-10.
12. MAYER DF, KUSHWAHA SS: Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases. Curr Opin Rheumatol 2003; 15: 219-25.
13. FLANAGAN WM, CRABTREE GR: Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition. Ann NY Acad Sci 1993; 696: 31-7.
14. De RYCKE L, VERHELST X, KRUITHOF E et al.: Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 299-302.
15. BOBBIO-PALLAVICINI F, ALPINI C, CAPORALI R et al.: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6: R264-72.
16. KUROKI A, MOLL T, LOPEZ-HOYOS M et al.: Enforced Bcl-2 expression in B lymphocytes induces rheumatoid factor and antiDNA production, but the Yaa mutation promotes only anti-DNA production. Eur J Immunol 2004; 34: 1077-84.
17. Van VENROOIJ WJ, PRUIJN GJM: Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000; 2: 249-51.
18. OSHIRO S, KOCHINDA T, TANA T et al.: A patient with adult-onset type II citrullinemia on long-term hemodialysis: reversal of clinical symptoms and brain MRI findings. Am J Kidney Dis 2002; 39: 189-92.
19. PAPPAS PA, TZAKIS AG, GAYNOR JJ et al.: An analysis of the association between serum citrulline and acute rejection among 26 recipients of intestinal transplant. Am J Transplant 2004; 4: 1124-32.
20. Van de POLL MCG, SOETERS PB, DEUTZ NEP, FEARON KCH, DEJONG CHC: Renal metabolism of amino acids: its role in inter-organ amino acid exchange. Am J Clin Nutr 2004; 79: 185-97.